New combo therapy targets breast cancer brain metastases
NCT ID NCT07454668
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether combining the targeted drug trastuzumab deruxtecan (T-DXd) with precise radiation (SRS) is safe for people with HER2-positive breast cancer that has spread to the brain. Up to 20 participants will receive the drug by IV every three weeks along with a single session of focused radiation. The main goal is to find the best dose and check for severe side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trastuzumab deruxtecan (T-DXd) and stereotactic radiosurgery (SRS)
What this could lead to
If this combination proves safe, it could lead to a new way to control brain metastases in HER2-positive breast cancer, potentially improving outcomes for patients.
What could go wrong
This is a very early Phase 1 trial with only 20 people, focused on safety and dosing. It may not show enough benefit to move forward, and side effects from the drug or radiation could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida, 33176, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••